Clinical trials: Hand Dermatitis
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- TRuE-CHE1 (NCT05219864)
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 49 sites in United States, Canada and 4 more
- Sponsor
- Incyte Corporation
Contact Dermatitis of Hands
The Effectiveness and Safety of Niacinamide 4% and Virgin Coconut Oil 30% for Secondary Prevention of Occupational Hand Dermatitis
Occupational hand dermatitis (OHD) often occurs in intensive care unit (ICU) nurses, especially in individuals who are vulnerable due to irritant exposure e.g. hand rub alcohol and repeated hand washing activities.
- Trial name
- NCT04218500
- Testing
- Niacinamide 4%, Virgin Coconut oil 30%
- Where
- Indonesia
- Volunteers
- 92 people
- Sponsor
- Universitas Indonesia
Hand Eczema
Hand Eczema in the Health Care Sector
This project aims to investigate the prevalence of bacterial colonization and associated factors in health care workers with hand eczema with focus on Staphylococcus aureus.
- Trial name
- NCT04449575
- Testing
- eSwabs
- Where
- Denmark
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Chronic Hand Eczema (CHE)
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- TRuE-CHE2 (NCT05233410)
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 39 sites in United States, Bulgaria and 5 more
- Sponsor
- Incyte Corporation
Hand Foot Skin Syndrome
Topical Cosmetic Products for Hand and Foot Syndrome
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing…
- Trial name
- NCT06586073
- Testing
- cosmetic products
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Dermophisiologique s.r.l
Hand Dermatitis
FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults
Hand dermatitis, (a rash, or eczema, on the hands) is a common skin condition that affects approximately 10% of the population. It can be caused by a wide variety of things, such as allergens or irritants.
- Trial name
- FiteBac (NCT01950494)
- Testing
- fiteBac Hand Sanitizer
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Jewish Health
Chronic Hand Eczema
Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)
This study is a multicentre, double-blinded, randomized, placebo-controlled, clinical trial with open-label extension. The purpose and aim of this study is to investigate the efficacy and safety of roflumilast (PDE4-inhibitor) in…
- Trial name
- NCT05682859
- Testing
- Roflumilast 500 Mcg Oral Tablet
- Where
- Denmark
- Volunteers
- 41 people
- Sponsor
- Jacob Pontoppidan Thyssen
Colorectal Cancer, Metastases
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
The study is a two-arm randomised phase III trial. Patients will be randomised to receive capecitabine (arm A) or S-1 (arm B). Bevacizumab may be added according to the choice of the investigator.
- Trial name
- SALTO (NCT01918852)
- Testing
- Capecitabine, Teysuno, Bevacizumab
- Where
- 24 sites in Netherlands
- Volunteers
- 161 people
- Sponsor
- Dutch Colorectal Cancer Group
Hand and Foot Syndrome, Erythrodysesthesia Syndrome
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of malignancy-related mortality. Capecitabine has been approved for the treatment of colorectal cancer as first-line therapy.
- Conditions
- Hand and Foot Syndrome, Erythrodysesthesia Syndrome, HFS, Colorectal Cancer
- Trial name
- HFS (NCT05327751)
- Testing
- Celecoxib 200mg, Capecitabine-based chemotherapy
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Ovarian Neoplasm
DOXIL for Consolidation Therapy in Ovarian Cancer.
The primary objective for this study is to evaluate the development, frequency and severity of hand foot syndrome (HFS) in ovarian cancer subjects treated with Doxil®, as consolidation therapy, on an every two week schedule.
- Trial name
- NCT00248248
- Testing
- liposomal doxorubicin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Southeastern Gynecologic Oncology
Hand Eczema
LEO19123 Cream in the Treatment of Hand Eczema
To compare the efficacy and safety of two different dose combinations of LEO19123 cream (calcipotriol and LEO80122) with LEO19123 cream vehicle for 3 weeks in the treatment of patients with hand eczema.
- Trial name
- NCT00404196
- Testing
- Calcipotriol and LEO80122 (LEO19123 cream)
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- LEO Pharma
Palmar-plantar Erythrodysesthesia
Topical Antiperspirant for Hand-Foot Syndrome
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved…
- Trial name
- NCT00213993
- Testing
- antiperspirant
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Hand Eczema, Foot Eczema
Treatment of Staphylococcus Aureus Colonization in Hand Eczema
Atopic dermatitis is a chronic disease characterized by itching and eczematous lesions. In adults, eczema commonly localizes to the hands or feet.
- Trial name
- NCT01591785
- Testing
- Retapamulin 1% ointment
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Gary Goldenberg
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Hand and Foot Syndrome
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and…
- Trial name
- NCT00767689
- Testing
- Vitamin B 6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Cook County Health
Atopic Dermatitis
Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.
The purpose of this study is to investigate the comparative efficacy, safety and efficiency of ciclosporin microemulsion and alitretinoin in adults with severe atopic hand dermatitis.
- Trial name
- TocyDD (NCT01231854)
- Testing
- Ciclosporin, Alitretinoin
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Technische Universität Dresden
Cancer
The Preventive Effect of Chemotherapy-induced Hand-foot Syndrome
this study will use traditional Chinese medicine bath with no obvious side effects combined with case tracking management mode to form nursing measures to prevent hand foot syndrome.
- Trial name
- NCT06441513
- Testing
- Chinese traditional medicine nursing combined with case tracking management, Health Education
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University Third Hospital
Dermatologic Complications, Palmar-plantar Erythrodysesthesia
Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer
RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with…
- Conditions
- Dermatologic Complications, Palmar-plantar Erythrodysesthesia, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00486213
- Testing
- pyridoxine hydrochloride
- Where
- Singapore
- Volunteers
- 210 people
- Sponsor
- National Cancer Centre, Singapore
Chronic Hand Eczema
Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
The purpose of this extension trial is to evaluate the long-term safety of delgocitinib. Subjects will visit the clinic every 4 week to assess the safety and efficacy of the treatment, until Week 36.
- Trial name
- DELTA 3 (NCT04949841)
- Testing
- Delgocitinib
- Where
- 95 sites in Belgium, Canada and 8 more
- Volunteers
- 801 people
- Sponsor
- LEO Pharma
Grade 2 Hand-foot Syndrom
Efficacy of the Cosmetic Product "Onco-Repair" on Grade 2 Hand Foot Syndrome
The aim of the study is to assess the restorative efficacy of the cosmetic product "Onco-Repair" vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
- Trial name
- OCRP (NCT03612011)
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Quanta Medical